by Truveta Research | Jul 16, 2025 | Research, Research Insights
The proportion of patients initiating treatment for multiple sclerosis (MS) with a high efficacy disease-modifying therapy (DMT) more than doubled from 2018 to 2025, reflecting evolving clinical guidelines. Use of oral and injectable therapies showed a gradual decline...
